266 related articles for article (PubMed ID: 29719618)
1. ONC201 kills breast cancer cells
Greer YE; Porat-Shliom N; Nagashima K; Stuelten C; Crooks D; Koparde VN; Gilbert SF; Islam C; Ubaldini A; Ji Y; Gattinoni L; Soheilian F; Wang X; Hafner M; Shetty J; Tran B; Jailwala P; Cam M; Lang M; Voeller D; Reinhold WC; Rajapakse V; Pommier Y; Weigert R; Linehan WM; Lipkowitz S
Oncotarget; 2018 Apr; 9(26):18454-18479. PubMed ID: 29719618
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
3. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
4. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
5. ONC201-Induced Mitochondrial Dysfunction, Senescence-like Phenotype, and Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL.
Mishukov A; Odinokova I; Mndlyan E; Kobyakova M; Abdullaev S; Zhalimov V; Glukhova X; Galat V; Galat Y; Senotov A; Fadeev R; Artykov A; Gasparian ME; Solovieva M; Beletsky I; Holmuhamedov E
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555190
[TBL] [Abstract][Full Text] [Related]
6. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
7. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
Ralff MD; Jhaveri A; Ray JE; Zhou L; Lev A; Campbell KS; Dicker DT; Ross EA; El-Deiry WS
Oncotarget; 2020 Oct; 11(42):3753-3769. PubMed ID: 33144917
[TBL] [Abstract][Full Text] [Related]
8. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
9. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
[TBL] [Abstract][Full Text] [Related]
10. A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Atkins SLP; Greer YE; Jenkins S; Gatti-Mays ME; Houston N; Lee S; Lee MJ; Rastogi S; Sato N; Burks C; Annunziata CM; Lee JM; Nagashima K; Trepel JB; Lipkowitz S; Zimmer AS
Oncologist; 2023 Oct; 28(10):919-e972. PubMed ID: 37279797
[TBL] [Abstract][Full Text] [Related]
11. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
[TBL] [Abstract][Full Text] [Related]
12. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
Zhang Y; Tapinos N; Lulla R; El-Deiry WS
Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
[TBL] [Abstract][Full Text] [Related]
13. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
14. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
15. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.
Fennell EMJ; Aponte-Collazo LJ; Pathmasiri W; Rushing BR; Barker NK; Partridge MC; Li YY; White CA; Greer YE; Herring LE; Lipkowitz S; Sumner SCJ; Iwanowicz EJ; Graves LM
Front Pharmacol; 2023; 14():1136317. PubMed ID: 37063293
[TBL] [Abstract][Full Text] [Related]
17. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
18. Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.
Zhao R; Li Y; Gorantla S; Poluektova LY; Lin H; Gao F; Wang H; Zhao J; Zheng JC; Huang Y
Antiviral Res; 2019 Aug; 168():134-145. PubMed ID: 31158413
[TBL] [Abstract][Full Text] [Related]
19. ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.
Fang Z; Wang J; Clark LH; Sun W; Yin Y; Kong W; Pierce SR; West L; Sullivan SA; Tran AQ; Prabhu VV; Zhou C; Bae-Jump V
Am J Cancer Res; 2018; 8(8):1551-1563. PubMed ID: 30210923
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
